Propolis for Patients With Chronic Kidney Disease.
Propolis for Patients With Chronic Kidney Disease.
NCT ID: NCT04411758 Phase: NA Status: COMPLETED Enrollment: 24 Completion: 2023-12-31
Conditions
Chronic Kidney Diseases, Inflammation
Interventions
Propolis, Placebo
Summary
To evaluate the effects of propolis extract on inflammation in participants with chronic kidney disease.
Specific objectives
To assess before and after the intervention period:
- The expression of transcription factors (nuclear factor-kB), antioxidant enzymes (heme-oxygenase-1), inflammasome receptor, peroxisome proliferator-activated receptor-γ, as well as the levels of inflammatory cytokines (IL-6, Tumor nuclear factor-α, C-reactive protein, interleukin 1) and E-selectin adhesion molecules;
- The levels of protein expression of inflammatory markers and antioxidant enzymes;
- The profile of the intestinal microbiota of stool samples from the research participants;
- Plasma levels of substances reactive to thiobarbituric acid and oxidized low density lipoprotein as a marker of oxidative stress;
- Routine and anthropometric laboratory variables, indicative of the metabolic profile of the research participants;
- Assess blood pressure, 6-minute walk test, recovery heart rate and chair lift test to assess the functional capacity of the research participants;
- Assess atherogenic risk;
- Food intake and nutritional status; Compare data between the intervention and control groups.
Primary Outcome
Change in cytokines plasma levels measured by ELISA after supplementation with propolis.